A
Arnon Nagler
Researcher at Sheba Medical Center
Publications - 1435
Citations - 51740
Arnon Nagler is an academic researcher from Sheba Medical Center. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 98, co-authored 1316 publications receiving 44298 citations. Previous affiliations of Arnon Nagler include French Institute of Health and Medical Research & University of Paris.
Papers
More filters
Journal ArticleDOI
Second reduced intensity conditioning allogeneic transplant as a rescue strategy for acute leukaemia patients who relapse after an initial RIC allogeneic transplantation: analysis of risk factors and treatment outcomes.
Radovan Vrhovac,Myriam Labopin,Fabio Ciceri,Juergen Finke,Ernst Holler,Johanna Tischer,Bruno Lioure,John G. Gribben,Lothar Kanz,Didier Blaise,Peter Dreger,Gerhard Held,Renate Arnold,Arnon Nagler,Mohamad Mohty +14 more
TL;DR: In patients with acute myelogenous, biphenotypic and undifferentiated leukaemia, duration of remission following RIC1 >225 days, presence of CR at RIC2, patient’s Karnofsky performance status >80 at Ric2 and non-myeloablative conditioning were found to be the strongest predictors of patients’ favourable outcome.
Journal ArticleDOI
Outcomes after use of two standard ablative regimens in patients with refractory acute myeloid leukaemia: a retrospective, multicentre, registry analysis.
Arnon Nagler,Bipin N. Savani,Myriam Labopin,Emmanuelle Polge,Jakob Passweg,Jürgen Finke,Slawomira Kyrcz-Krzemien,Liisa Volin,Achilles Anagnostopoulos,Mahmoud Aljurf,Dietrich W. Beelen,Stephane Vigouroux,Noel Milpied,Felipe Suarez,Mohamad Mohty +14 more
TL;DR: From a practical standpoint, the use of intravenous busulfan plus cyclophosphamide is likely to be a valid and efficient alternative to cycloph phosphamide plus TBI conditioning regimen for patients with refractory acute myeloid leukaemia, especially for those transplant centres without access to radiation facilities.
Journal ArticleDOI
Radioimmunotherapy for Stem Cell Transplantation in Non-Hodgkin's Lymphoma: In Pursuit of a Complete Response
TL;DR: The data so far suggest that the use of RIT in the autologous setting can improve clinical outcome with no added toxicity in these patients, whereas similar positive findings have been reported in preliminary studies of yttrium-90 ibritumomab tiuxetan combined with RIC and alloSCT in high-risk patients.
Journal ArticleDOI
Haploidentical vs. unrelated allogeneic stem cell transplantation for acute lymphoblastic leukemia in first complete remission: on behalf of the ALWP of the EBMT.
Noga Shem-Tov,Christophe Peczynski,Myriam Labopin,Maija Itälä-Remes,Didier Blaise,Hélène Labussière-Wallet,Gérard Socié,Nicolaus Kröger,Stephan Mielke,Boris V. Afanasyev,Patrice Chevallier,Johanna Tischer,Grzegorz Helbig,Pavel Jindra,Zinaida Peric,Sebastian Giebel,Mohamad Mohty,Arnon Nagler +17 more
TL;DR: Results of adult patients with ALL in CR1 receiving Haplo Allo-SCT are comparable to MUD or MMUD transplants and should be considered as a clinically relevant option for patients lacking a matched sibling donor.
Journal ArticleDOI
Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy
Mohamed A. Kharfan-Dabaja,Ambuj Kumar,Ernesto Ayala,Mahmoud Aljurf,Taiga Nishihori,Rebecca A. Marsh,Lauri Burroughs,Navneet S. Majhail,A. Samer Al-Homsi,Zaid S. Al-Kadhimi,Merav Bar,Alice Bertaina,Jaap Jan Boelens,Richard E. Champlin,Sonali Chaudhury,Zachariah DeFilipp,Bhagirathbhai Dholaria,Areej El-Jawahri,Suzanne Fanning,Ellen Fraint,Usama Gergis,Sergio Giralt,Betty K. Hamilton,Shahrukh K. Hashmi,Biljana Horn,Yoshihiro Inamoto,David A. Jacobsohn,Tania Jain,Laura Johnston,Abraham S. Kanate,Ankit Kansagra,Adetola A. Kassim,Leslie S. Kean,Carrie L. Kitko,Jessica Knight-Perry,Joanne Kurtzberg,Hien D. Liu,Margaret L. MacMillan,Zahra Mahmoudjafari,Marco Mielcarek,Mohamad Mohty,Arnon Nagler,Eneida R. Nemecek,Timothy S. Olson,Betul Oran,Miguel-Angel Perales,Susan E. Prockop,Michael A. Pulsipher,Iskra Pusic,Marcie L. Riches,Cesar Rodriguez,Rizwan Romee,Gabriela Rondon,Ayman Saad,Nina Shah,Peter J. Shaw,Shalini Shenoy,Jorge Sierra,Julie Talano,Michael R. Verneris,Paul Veys,John E. Wagner,Bipin N. Savani,Mehdi Hamadani,Paul A. Carpenter +64 more
TL;DR: The authors surveyed a panel of allogeneic hematopoietic cell transplantation (allo-HCT) experts in an attempt to standardize these definitions, finding consensus for neutrophil and platelet recovery, graft rejection, graft failure, poor graft function, and donor chimerism but not for delayed engraftment.